Smart contact lens monitors eye pressure, delivers drug without electronics
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- Terasaki Institute researchers led by Yangzhi Zhu designed a theranostic contact lens that tracks intraocular pressure and releases glaucoma drugs from an embedded microfluidic chamber, triggered by cornea-shape changes — with no electronics or battery required.
- The device performed reliably in live tests on rabbits — one group with ocular hypertension and a control group — and on ex vivo cow eyes, according to the study published Wednesday in Science Translational Medicine.
- Triggerfish, Sensimed's FDA-approved continuous ocular monitor, is "amazing" but limited by rigid, nontransparent components that cause mechanical mismatch and discomfort, flaws Zhu said his all-polymer design sidesteps.
- James Wolffsohn, an optometry professor at Aston University uninvolved in the study, called the device "generally quite clever" but warned glaucoma drugs are slow-acting, meaning the lens would need to learn a patient's pressure pattern and release medication pre-emptively.
- The Terasaki Institute filed a patent for the pressure-monitoring lens last year and plans a small human trial next; FDA approval of the monitoring component will likely come faster than the drug-dispensing component, which faces more rigorous regulatory standards.
- Zhu described the technology as an "open-source platform" that could be extended beyond glaucoma to other ocular, neurological, and systemic diseases.
- The article notes that Verily, a Google spinoff, shelved its glucose-sensing smart contact lens program in 2018, underscoring the difficulty of bringing smart-lens products to market.
Why it matters: Glaucoma blinds roughly half of patients before they know they have it, partly because in-office pressure checks happen every few months and daily-drop adherence fades over time. A single lens that monitors continuously and self-doses attacks both failure points — if human trials replicate the rabbit results and the FDA clears both monitoring and drug-delivery components.
